Tryptophan metabolism in the joint diseases
Acta Vitaminologica Et Enzymologica
|January 1, 1975
Summary
Rheumatoid arthritis and osteoarthritis show distinct tryptophan metabolism in synovial fluid. Serotonin pathway differences were minor, but monoamine oxidase activity was higher in osteoarthritis.
Area of Science:
- Biochemistry
- Immunology
- Metabolomics
Background:
- Tryptophan metabolism, particularly via the kynurenine and serotonin pathways, is implicated in inflammatory processes.
- Understanding specific metabolic alterations in joint diseases like rheumatoid arthritis (RA) and osteoarthritis (OA) is crucial for elucidating disease mechanisms.
Purpose of the Study:
- To investigate the specificity of tryptophan metabolism in the synovial fluid, blood, and urine of RA and OA patients.
- To determine the distinct roles of the kynurenine and serotonin pathways in the pathogenesis of these joint diseases.
- To create a metabolic map of tryptophan in synovial fluid.
Main Methods:
- Analysis of tryptophan metabolites in synovial fluid, blood, and urine from RA and OA patients.
- Comparative analysis of metabolic pathways, including the kynurenine pathway (anthranilic acid, kynurenic acid, nicotinic acid) and the 5-hydroxytryptophan pathway (serotonin, 5-hydroxyindole acetic acid).
- Measurement of monoamine oxidase activity in synovial fluid.
Main Results:
- Rheumatoid arthritis showed predominant tryptophan metabolism to anthranilic acid via the kynurenine pathway.
- Osteoarthritis was characterized by the kynurenic acid and nicotinic acid pathways.
- No significant differences in 5-hydroxytryptamine and 5-hydroxyindole acetic acid levels were observed between RA and OA in synovial fluid.
- Monoamine oxidase activity was significantly higher in the synovial fluid of osteoarthritis patients compared to rheumatoid arthritis patients.
Conclusions:
- Tryptophan metabolism exhibits distinct patterns in rheumatoid arthritis and osteoarthritis, particularly through the kynurenine pathway.
- While serotonin pathway metabolites show no major differences, altered monoamine oxidase activity in osteoarthritis suggests a role in joint disease pathogenesis.
- These findings highlight specific metabolic signatures that may contribute to the differential mechanisms underlying RA and OA.
More Related Videos
09:31PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase
Published on: September 26, 2020
![Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
08:33Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
Published on: September 21, 2021
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Amino Acid Biosynthetic Pathways
Amino acid biosynthesis is essential for cell growth, protein synthesis, and metabolic regulation. Cells generate essential and non-essential amino acids from metabolic intermediates to sustain vital biological functions. These intermediates originate from key metabolic pathways: glycolysis, the tricarboxylic acid (TCA) cycle, and the pentose phosphate pathway. Important precursors include α-ketoglutarate, pyruvate, oxaloacetate, phosphoenolpyruvate, and erythrose-4-phosphate, which provide...